Bryce Point Capital LLC Invests $485,000 in Zoetis Inc. (NYSE:ZTS)

Bryce Point Capital LLC purchased a new position in Zoetis Inc. (NYSE:ZTS - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 2,977 shares of the company's stock, valued at approximately $485,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Mission Wealth Management LP boosted its position in Zoetis by 2.0% during the 4th quarter. Mission Wealth Management LP now owns 2,938 shares of the company's stock valued at $479,000 after acquiring an additional 59 shares in the last quarter. VeraBank N.A. lifted its stake in shares of Zoetis by 4.1% during the 4th quarter. VeraBank N.A. now owns 1,562 shares of the company's stock worth $254,000 after purchasing an additional 62 shares during the last quarter. HUB Investment Partners LLC grew its stake in Zoetis by 4.7% in the fourth quarter. HUB Investment Partners LLC now owns 1,373 shares of the company's stock valued at $224,000 after purchasing an additional 62 shares during the last quarter. Procyon Advisors LLC raised its holdings in Zoetis by 1.4% in the fourth quarter. Procyon Advisors LLC now owns 4,712 shares of the company's stock worth $768,000 after purchasing an additional 63 shares in the last quarter. Finally, Deseret Mutual Benefit Administrators lifted its position in shares of Zoetis by 6.6% during the fourth quarter. Deseret Mutual Benefit Administrators now owns 1,045 shares of the company's stock valued at $170,000 after buying an additional 65 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

ZTS has been the topic of a number of analyst reports. Barclays lifted their price objective on shares of Zoetis from $242.00 to $244.00 and gave the stock an "overweight" rating in a research report on Friday, February 14th. StockNews.com upgraded Zoetis from a "hold" rating to a "buy" rating in a report on Friday, March 7th. Morgan Stanley lowered their price objective on Zoetis from $243.00 to $238.00 and set an "overweight" rating for the company in a research report on Friday, February 14th. Piper Sandler upped their target price on Zoetis from $200.00 to $205.00 and gave the company an "overweight" rating in a research report on Thursday, February 27th. Finally, Stifel Nicolaus lowered their price target on Zoetis from $210.00 to $180.00 and set a "buy" rating for the company in a report on Tuesday, January 7th. One equities research analyst has rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Buy" and an average target price of $215.90.

Insider Activity at Zoetis

In other news, EVP Roxanne Lagano sold 326 shares of the business's stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total value of $55,804.68. Following the completion of the sale, the executive vice president now directly owns 16,107 shares in the company, valued at $2,757,196.26. The trade was a 1.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Willie M. Reed sold 1,210 shares of Zoetis stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total transaction of $201,029.40. Following the completion of the sale, the director now directly owns 11,245 shares in the company, valued at $1,868,244.30. This represents a 9.71 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 1,862 shares of company stock worth $312,254 in the last 90 days. Corporate insiders own 0.16% of the company's stock.

Zoetis Stock Performance

Shares of NYSE:ZTS traded down $9.17 during midday trading on Thursday, reaching $144.38. The company's stock had a trading volume of 1,435,225 shares, compared to its average volume of 2,614,277. The firm has a market capitalization of $64.65 billion, a PE ratio of 26.34, a P/E/G ratio of 2.78 and a beta of 0.92. The stock has a fifty day moving average of $163.46 and a 200 day moving average of $172.01. Zoetis Inc. has a twelve month low of $139.70 and a twelve month high of $200.33. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09.

Zoetis (NYSE:ZTS - Get Free Report) last posted its earnings results on Thursday, February 13th. The company reported $1.40 EPS for the quarter, topping the consensus estimate of $1.37 by $0.03. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The firm had revenue of $2.32 billion for the quarter, compared to analyst estimates of $2.30 billion. On average, equities analysts expect that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be paid a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a dividend yield of 1.39%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis's payout ratio is currently 36.56%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.